FDA gives clearance for Scientific Analytics and Hospital for Special Surgery for computer-vision collaboration

Pexels
- Pexels
0Comments

The FDA gave 510(k) medical device designation to Scientific Analytics (SAI) for DARI Health, a computer-vision-powered motion analysis technology.

Scientific Analytics will use this designation in a strategic collaboration with the Hospital for Special Surgery (HSS).

DARI Health will quantify and display human movement patterns and techniques to help in pre- and post-rehabilitation evaluation, physical therapy and many other musculoskeletal advancements.

“We are excited to work with HSS to advance new standards in motion health and disrupt areas of health care where we continue to build upon our innovation leadership — as indicated by the recent FDA clearance of DARI Health,” said Todd Gleason, president and CEO at Scientific Analytics.

SAI has over 425 billion data points throughout wellness, military, athletics and health care focused on human motion.

For its part, HSS said it was excited to work with SAI for better musculoskeletal injury prevention and treatment.

“SAI’s state-of-the-art technology complements additions and advancements to our clinical talent, physical locations, digital offerings and education delivery,” said Louis Shapiro, president and CEO of HSS. “This emerging HSS ecosystem including the DARI platform will help set new standards in the quality and availability of musculoskeletal wellness, assessment devices, and solutions.”



Leave a Reply

Your email address will not be published. Required fields are marked *

Related

LOCATE BIO: CognitOss Granted FDA Breakthrough Device Designation

LOCATE BIO: CognitOss Granted FDA Breakthrough Device Designation

CognitOss is designed to treat osteomyelitis, a debilitating inflammatory bone infection

NORTHSTAR MEDICAL RADIOISOTOPES: Announces FDA Approval for Enhanced U.S. Mo-99 Radioisotope Production Capacity

NORTHSTAR MEDICAL RADIOISOTOPES: Announces FDA Approval for Enhanced U.S. Mo-99 Radioisotope Production Capacity

Concentrated molybdenum-98 (cMo-98) enables up to four-fold increase of critical medical radioisotope Mo-99 production in U.S.

King & Spalding announced that Marisa Maleck rejoins the firm as a partner in the FDA and Life Sciences team

KING & SPALDING: FDA and Life Sciences Team Adds Partner in Washington

King & Spalding announced that Marisa Maleck rejoins the firm as a partner in the FDA and Life Sciences team, which is part of the Government Matters practice.

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from FDA Reporter.